FINWIRES · TerminalLIVE
FINWIRES

Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients

By

Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.

The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.

Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.

Shares of Altimmune rose more than 3% in Thursday trading.

Price: $3.07, Change: $+0.09, Percent Change: +3.15%

Related Articles

Wire

Dell Technologies Unit Wins $9.69 Billion US Navy Contract

Dell Technologies (DELL) unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative.The agreement will streamline software acquisition across the Defense Department, the intelligence community, and the US Coast Guard, according to a statement.The deal will allow clients to procure Microsoft (MSFT) software licenses, cloud subscriptions, and Software Assurance, according to the Department.

$DELL$MSFT
Wire

Dave to Replace American Woodmark in S&P SmallCap 600

Dave (DAVE) is set to replace American Woodmark (AMWD) in the S&P SmallCap 600 before trading begins Monday, S&P Dow Jones Indices said.MasterBrand (MBC) is acquiring American Woodmark in a deal expected to close May 29, the S&P Global (SPGI) unit said Wednesday in a statement.Dave shares rose 4.2% in after-hours trading.

$AMWD$DAVE$SPGI
Wire

Citi Trends Reports Preliminary Fiscal Q1 Sales, Lifts FY Comparable-Store Sales Outlook

Citi Trends (CTRN) reported fiscal Q1 preliminary sales late Wednesday of $230.9 million and raised its full-year outlook for comparable-store sales growth.A year earlier, sales were $201.7 million.Comparable-store sales growth in fiscal 2026 is expected to range from 8% to 10%, compared with the prior 5% to 7% forecast, the company said.Citi Trends also lifted its full-year adjusted EBITDA guidance to $35 million to $40 million from the previous outlook of $34 million to $38 million.Citi Trends shares rose 10% in after-hours trading.

$CTRN